Prediction of clearance and volume of distribution in the obese from normal weight subjects: An allometric approach

Clinical Pharmacokinetics

Volumn 51, Issue 8, 2012, Pages 527-542

  Mahmood, Iftekhar ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

body weight; metabolic clearance rate; obesity; pharmacokinetic modelling; pharmacokinetics

Indexed keywords

CARBAMAZEPINE; CEFAZOLIN; CIMETIDINE; DAPTOMYCIN; LITHIUM; PHENAZONE; PROCAINAMIDE; PROPOFOL; REMIFENTANIL; THEOPHYLLINE; TOBRAMYCIN; VANCOMYCIN;

ACCURACY; ADOLESCENT; ALLOMETRY; ARTICLE; BODY MASS; BODY WEIGHT; CHILD; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; HUMAN; MAJOR CLINICAL STUDY; OBESITY; PREDICTIVE VALIDITY; PRIORITY JOURNAL; SCHOOL CHILD;

ADULT; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, BIOLOGICAL; OBESITY; PHARMACEUTICAL PREPARATIONS; TISSUE DISTRIBUTION;

EID: 84863455332     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11631630-000000000-00000     Document Type: Article

References (49)

1. Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 2004; 58: 119-33 (Pubitemid 39043992)
2. Zavorsky GS. Cardiopulmonary aspects of obesity in women. Obstet Gynecol Clin North Am 2009; 36: 267-84
3. Mahmood I. Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development. Adv Drug Deliv Rev 2007; 59: 1177-92 (Pubitemid 47615206)
4. Mahmood I. Prediction of drug clearance in children: impact of allometric exponents, body weight, and age. Ther Drug Monit 2007; 29: 271-8 (Pubitemid 47262255)
5. Mahmood I. Prediction of drug clearance in children from adults: a comparison of several allometric methods. Br J Clin Pharmacol 2006; 61: 545-57
6. Caraco Y, Zylber-Katz E, Berry EM, et al. Antipyrine disposition in obesity: evidence for negligible effect of obesity on hepatic oxidative metabolism. Eur J Clin Pharmacol 1995; 47: 525-30
7. Caraco Y, Zylber-Katz E, Berry EM, et al. Carbamazepine pharmacokinetics in obese and lean subjects. Ann Pharmacother 1995; 29: 843-7
8. Pai MP, Jeffrey P, Norenberg JP, et al. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob Agents Chemother 2007; 51: 2741-7 (Pubitemid 47206208)
9. Reiss RA, Haas CE, Karki SD, et al. Lithium pharmacokinetics in the obese. Clin Pharmacol Ther 1994; 55: 392-8 (Pubitemid 24172962)
10. Christoff PB, Conti DR, Naylor C, et al. Procainamide disposition in obesity. Drug Intell Clin Pharm 1983; 17: 516-22 (Pubitemid 13068107)
11. Wyman MG, Goldreyer BN, Cannon DS, et al. Factors influencing procainamide total body clearance in the immediate postmyocardial infarction period. J Clin Pharmacol 1981; 21: 20-5 (Pubitemid 11149285)
12. Schnider TW, Minto CF, Gambus PL, et al. The influence of method of administration and covariates on the pharmacokinetics of propofol in adult volunteers. Anesthesiology 1998; 88: 1170-82 (Pubitemid 28216859)
13. Servin F, Farinotti R, Haberer JP, et al. Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide: a clinical and pharmacokinetic study. Anesthesiology 1993; 78: 657-65 (Pubitemid 23110039)
14. Van Kralingen S, Diepstraten J, Peeters MY, et al. Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients. Clin Pharmacokinet 2011; 50: 739-50
15. Egan TD, Huizinga B, Gupta SK, et al. Remifentanil pharmacokinetics in obese versus lean patients. Anesthesiology 1998; 89: 562-73 (Pubitemid 28423952)
16. Egan TD, Lemmens HJ, Fiset P, et al. The pharmacokinetics of the new shortacting opioid remifentanil (GI87084B) in healthy adult male volunteers. Anesthesiology 1993; 79: 881-92 (Pubitemid 23339045)
17. Scheld WM, Spyker DA, Donowitz GR, et al. Moxalactam and cefazolin: comparative pharmacokinetics in normal subjects. Antimicrob Agents Chemother 1981; 19: 613-9 (Pubitemid 11079469)
18. Van Kralingen S, Taks M, Diepstraten J, et al. Pharmacokinetics and protein binding of cefazolin in morbidly obese patients. Eur J Clin Pharmacol 2011; 67: 985-92
19. Grahnén A, von Bahr C, Lindström B, et al. Bioavailability and pharmacokinetics of cimetidine. Eur J Clin Pharmacol 1979; 16: 335-40 (Pubitemid 10212154)
20. Bauer LA, Wareing-Tran C, Edwards WA, et al. Cimetidine clearance in the obese. Clin Pharmacol Ther 1985; 37: 425-30 (Pubitemid 15238889)
21. Bodemar G, Norlander B, Walan A. Pharmacokinetics of cimetidine after single doses and during continuous treatment. Clin Pharmacokinet 1981; 6: 306-15 (Pubitemid 12219235)
22. Conrad KA, Nyman DW. Effects of metoprolol and propranolol on theophylline elimination. Clin Pharmacol Ther 1980; 28: 463-7 (Pubitemid 11253931)
23. Blouin RA, Elgert JF, Bauer LA. Theophylline clearance: effect of marked obesity. Clin Pharmacol Ther 1980; 28: 619-23 (Pubitemid 11254161)
24. Gal P, Jusko WJ, Yurchak AM, et al. Theophylline disposition in obesity. Clin Pharmacol Ther 1978; 23: 438-44 (Pubitemid 8327807)
25. Winslade NE, Adelman MH, Evans EJ, et al. Single-dose accumulation pharmacokinetics of tobramycin and netilmicin in normal volunteers. Antimicrob Agents Chemother 1987; 3: 605-9 (Pubitemid 17054345)
26. Blouin RA, Mann H J, Griffen WO, et al. Tobramycin pharmacokinetics in morbidly obese patients. Clin Pharmacol Ther 1979; 26: 508-12 (Pubitemid 10214576)
27. BlouinRA,BauerLA,MillerDD, et al.Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 1982; 21: 575-80 (Pubitemid 12070524)
28. Bauer LA, Black DJ, Lill JS. Vancomycin dosing in morbidity obese patients. Eur J Clin Pharmacol 1998; 54: 621-5 (Pubitemid 28531423)
29. Matzke GR, McGory RW, Halstenson CE, et al. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 1984; 25: 433-7 (Pubitemid 14129598)
30. Benet LZ, Oie S, Schwartz JB. Design and optimization of dosage regimens: pharmacokinetic data. In: Molinoff PB, Ruddon RW, editors. Goodman & Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 1707-92
31. Kleiber M. Body size and metabolism. Hilgardia 1932; 6: 315-51
32. Brody S, Procter RC, Ashworth US. Basal metabolism, endogenous nitrogen, creatinine and neutral sulphur excretions as functions of body weight. Univ Missouri Agric Exp Sta Res Bull 1934; 220: 1-40
33. Brody S. Bioenergetics and growth, with special reference to the efficiency complex in domestic animals. New York: Hafner Press, MacMillan Publishers, 1945
34. West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science 1997; 276: 122-6 (Pubitemid 27161259)
35. West GB, Brown JH, Enquist BJ. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science 1999; 284: 1677-9 (Pubitemid 29291379)
36. Peeters MY, Allegaert K, Blussé Van Oud-Alblas HJ, et al. Prediction of propofol clearance in children from an allometric model developed in rats, children and adults versus a 0.75 fixed-exponent allometric model. Clin Pharmacokinet 2010; 49: 269-75
37. Glazier DS. Beyond the '3/4-power law': variation in the intra-and interspecific scaling ofmetabolic rate in animals. BiolRev Camb Philos Soc 2005; 80: 611-62 (Pubitemid 43381262)
38. Packard GC, Birchard GF. Traditional allometric analysis fails to provide a valid predictive model formammalian metabolic rates. J Exp Biol 2008; 211 Pt 22: 3581-7
39. Bokma F. Evidence against universal metabolic allometry. Functional Ecology 2004; 18: 184-7 (Pubitemid 38504281)
40. White CR, Seymour RS. Sample size and mass range effects on the allometric exponent of basal metabolic rate. Comp Biochem Physiol A Mol Integr Physiol 2005; 142: 74-8 (Pubitemid 41265917)
41. White CR, Cassey P, Blackburn TM. Allometric exponents do not support a universal metabolic allometry. Ecology 2007; 88: 315-23 (Pubitemid 46596794)
42. Mahmood I. Application of fixed exponent 0.75 to the prediction of human drug clearance: an inaccurate and misleading concept. Drug Metabol Drug Interact 2009; 24: 57-81
43. Mahmood I. Theoretical versus empirical allometry: facts behind theories and application to pharmacokinetics. J Pharm Sci 2010; 99: 2927-33
44. Dodds PS, Rothman DH, Weitz JS. Re-examination of the "3/4-law" of metabolism. J Theor Biol 2001; 209: 9-27
45. Hayssen V, Lacy RC. Basal metabolic rates in mammals: toxonomic differences in the allometry of BMR and body mass. Comp Biochem Physiol 1985; 81A: 741-54
46. Bjö rkman S. Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children: how accurate are available scaling methods? Clin Pharmacokinet 2006; 45: 1-11
47. Weibel ER, Hoppeler H. Exercise-induced maximal metabolic rate scales with muscle aerobic capacity. J Exp Biol 2005; 208 Pt 9: 1635-44 (Pubitemid 40697612)
48. Snelling EP, Seymour RS, Matthews PG, et al. Scaling of resting and maximum hopping metabolic rate throughout the life cycle of the locust Locusta migratoria. J Exp Biol 2011; 214 (Pt 19): 3218-24
49. Karbowski J. Scaling of brain metabolism and blood flow in relation to capillary and neural scaling. PLoS One 2011; 6 (10): e26709